Rapoport, B. L., Davar, D., Simon, J., Bechter, O. E., Dalle, S., Wu, Y., Brungs, D., Giacomo, A. M. D., Eriksson, H., Mohr, P., Pezo, R. C., Ramelyte, E., Rivalland, G., Hoki, T., Sadeia, M., Zhang, Y., Kurland, E., Eggermont, A. M. (2026). Adaptive phase 2/3 study of EIK1001, a TLR7/8 dual agonist, in combination with pembrolizumab, as first-line therapy in participants with advanced melanoma (TeLuRide-006).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps9601